BioWorld

March 6, 2009

Proteon Snares $38M Round, and $550M Novartis Option

Proteon Therapeutics Inc. is banking on its lead product to clear a crucial Phase II study, the results of which could seal a $550 million deal with Novartis AG. (BioWorld Today) Read More

Optimer's Anti-Infective Pipeline Moving Ahead Via $33M Offering

Ortho Group Says Biologics Are no Longer 'Back in the Corner'

Obama Ties Health Reform To Prosperity of the U.S.

Isolagen Shares Jump 30% on Good Acne Trial Data

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...